Yinggang Qin, Conghuang Li, Guijian Liu, Baojin Hua*
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
Introduction: Circulating tumor cells(CTCs) have shown a good predictive effect on the effect and prognosis of solid tumor patients in many studies. In China, traditional Chinese medicine(TCM) is one of the treatments of non-small cell lung cancer(NSCLC). To investigate the predictive value of CTCs in patients with advanced NSCLC, we conducted the following research.
Case Presentation: A total of 63 patients diagnosed with NSCLC were nonrandomly divided into two groups. The peripheral blood was collected before treatment and after one-cycle treatment to count the number of CTCs; meanwhile, the imaging evaluation after 2-cycle treatment and the ultimate survival period were also investigated. The changes in the number of CTCs had a certain evaluative role in predicting the therapeutic effects of imaging (AUC=0.755, medium predictive value) (95% CI: 0.624~0.885), P=0.002; compared with the changes of tumor markers, AUCs of the number changes of CTCs and tumor markers were 0.734 (95% CI: 0.579~0.889), P=0.012 and At 0.730 (95% CI: 0.570~0.890), P=0.014, and there was no statistical significance in the predictive value; the predictive value in Group C-TCM (the AUC of ROC was 0.822 (95% CI: 0.653~0.992), P=0.005) was statistically significant than Group TCM (the AUC of ROC was 0.679 (95% CI: 0.456~0.902), P=0.135). In patients with CTCs >5 and ≤5, the average survival periods were 228.10 days (95% CI: 204.47~251.73) and 339.70 days (95% CI: 331.12~348.29), respectively, P=0.000.
Conclusion: CTCs have certain application value in predicting the efficacy and prognosis against NSCLC patients.
Circulating tumor cells, non-small cell lung cancer, traditional chinese medicine.
10.19193/0393-6384_2020_5_445